351 related articles for article (PubMed ID: 15036041)
61. Artificial antigens for HIV vaccine design.
Expert Rev Vaccines; 2007 Jun; 6(3):301. PubMed ID: 17542744
[No Abstract] [Full Text] [Related]
62. HIV vaccine development: perspective.
Bolognesi DP
Biotechnol Ther; 1991; 2(1-2):205-11. PubMed ID: 1845122
[No Abstract] [Full Text] [Related]
63. Paradigm change in immune correlation: cellular or humoral?
Matsuo K; Yamamoto N
Expert Rev Vaccines; 2010 Sep; 9(9):985-7. PubMed ID: 20822339
[No Abstract] [Full Text] [Related]
64. AIDS 1995. Vaccines and immunology: overview.
Montelaro RC; Wigzell H
AIDS; 1995; 9 Suppl A():S111-2. PubMed ID: 8819577
[No Abstract] [Full Text] [Related]
65. Vaccines against HIV.
Carmichael AJ; Sissons JG
QJM; 1995 Feb; 88(2):77-9. PubMed ID: 7704566
[No Abstract] [Full Text] [Related]
66. Mucosal immunity, HIV transmission, and AIDS.
Miller CJ; McGhee JR; Gardner MB
Lab Invest; 1993 Feb; 68(2):129-45. PubMed ID: 8441249
[No Abstract] [Full Text] [Related]
67. Is an HIV vaccine possible?
McMichael AJ; Hanke T
Nat Med; 1999 Jun; 5(6):612-4. PubMed ID: 10371492
[No Abstract] [Full Text] [Related]
68. What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials.
Gilbert PB; DeGruttola VG; Hudgens MG; Self SG; Hammer SM; Corey L
J Infect Dis; 2003 Jul; 188(2):179-93. PubMed ID: 12854072
[TBL] [Abstract][Full Text] [Related]
69. Live virus shows promise as AIDS vaccine.
Minn Med; 1993 Feb; 76(2):52. PubMed ID: 8433695
[No Abstract] [Full Text] [Related]
70. Alloimmunization for immune-based therapy and vaccine design against HIV/AIDS.
Shearer GM; Pinto LA; Clerici M
Immunol Today; 1999 Feb; 20(2):66-71. PubMed ID: 10098324
[TBL] [Abstract][Full Text] [Related]
71. Radical approach to HIV vaccine.
Nurs Stand; 1992 Sep 30-Oct 6; 7(2):17. PubMed ID: 1419714
[No Abstract] [Full Text] [Related]
72. Estimating Costs and Benefits of CTL Escape Mutations in SIV/HIV Infection.
Ganusov VV; De Boer RJ
PLoS Comput Biol; 2006 Mar; 2(3):e24. PubMed ID: 16604188
[TBL] [Abstract][Full Text] [Related]
73. What's the matter with HIV-directed killer T cells?
Wick D; Self SG
J Theor Biol; 2002 Nov; 219(1):19-31. PubMed ID: 12392972
[TBL] [Abstract][Full Text] [Related]
74. A condition for successful escape of a mutant after primary HIV infection.
Monteiro LH; Gonçalves CH; Piqueira JR
J Theor Biol; 2000 Apr; 203(4):399-406. PubMed ID: 10736216
[TBL] [Abstract][Full Text] [Related]
75. Moving ahead an HIV vaccine: use both arms to beat HIV.
Walker BD; Ahmed R; Plotkin S
Nat Med; 2011 Oct; 17(10):1194-5. PubMed ID: 21988996
[No Abstract] [Full Text] [Related]
76. Prospects for a human immunodeficiency virus/AIDS vaccine.
Murphy FA; Folks TM; Lairmore MD
Dev Biol Stand; 1990; 72():3-15. PubMed ID: 1704324
[No Abstract] [Full Text] [Related]
77. Houdini's box: towards an understanding of AIDS virus escape from the cytotoxic T-lymphocyte response.
O'Connor DH; Watkins DI
Immunogenetics; 1999 Nov; 50(3-4):237-41. PubMed ID: 10602884
[No Abstract] [Full Text] [Related]
78. The critical role of CD4(+) T-cell help in immunity to HIV.
Heeney JL
Vaccine; 2002 May; 20(15):1961-3. PubMed ID: 11983254
[TBL] [Abstract][Full Text] [Related]
79. HIV type 1 vaccine-induced cytotoxic T cell responses: potential role in vaccine efficacy.
Ada GL; McElrath MJ
AIDS Res Hum Retroviruses; 1997 Feb; 13(3):205-10. PubMed ID: 9115805
[No Abstract] [Full Text] [Related]
80. Novel strategies toward the development of an effective vaccine to prevent human immunodeficiency virus infection or acquired immunodeficiency virus.
Ensoli B; Cafaro A
AIDS Clin Rev; 2000-2001; ():23-61. PubMed ID: 10999215
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
